| Year |
Citation |
Score |
| 2024 |
Bruce C, Prassas I, Mokhtar M, Clarke B, Youssef E, Wang C, Yousef GM. Transforming diagnostics: The implementation of digital pathology in clinical laboratories. Histopathology. PMID 38516992 DOI: 10.1111/his.15178 |
0.43 |
|
| 2024 |
Chatanaka MK, Prassas I, Diamandis EP. Diagnostic and progression biomarkers in cerebrospinal fluid of Alzheimer's disease patients. Bmc Medicine. 22: 60. PMID 38331825 DOI: 10.1186/s12916-024-03270-w |
0.363 |
|
| 2024 |
Vasudevan Nampoothiri R, Avery L, Pasic I, Prassas I, Diamandis E, Michelis FV. Multiplex proteomics in the identification of potential biomarkers of very severe sinusoidal obstruction syndrome/veno-occlusive disease (SOS/VOD) in allogeneic hematopoietic cell transplant patients treated with defibrotide. Acta Haematologica. PMID 38330921 DOI: 10.1159/000535706 |
0.41 |
|
| 2023 |
Chatanaka MK, Avery LM, Pasic MD, Sithravadivel S, Rotstein D, Demos C, Cohen R, Gorham T, Wang M, Stengelin M, Mathew A, Wohlstadter J, Prassas I, Diamandis EP. The relationship between serum astroglial and neuronal markers and AQP4 and MOG autoantibodies. Research Square. PMID 38077014 DOI: 10.21203/rs.3.rs-3659922/v1 |
0.351 |
|
| 2023 |
Sohaei D, Thebault S, Avery LM, Batruch I, Lam B, Xu W, Saadeh RS, Scarisbrick IA, Diamandis EP, Prassas I, Freedman MS. Cerebrospinal fluid camk2a levels at baseline predict long-term progression in multiple sclerosis. Clinical Proteomics. 20: 33. PMID 37644477 DOI: 10.1186/s12014-023-09418-9 |
0.35 |
|
| 2023 |
Janket SJ, Fraser DD, Baird AE, Tamimi F, Sohaei D, Conte HA, Prassas I, Diamandis EP. Tachykinins and the potential causal factors for post-COVID-19 condition. The Lancet. Microbe. PMID 37327802 DOI: 10.1016/S2666-5247(23)00111-8 |
0.31 |
|
| 2023 |
Crescioli S, Correa I, Ng J, Willsmore ZN, Laddach R, Chenoweth A, Chauhan J, Di Meo A, Stewart A, Kalliolia E, Alberts E, Adams R, Harris RJ, Mele S, Pellizzari G, ... ... Prassas I, et al. B cell profiles, antibody repertoire and reactivity reveal dysregulated responses with autoimmune features in melanoma. Nature Communications. 14: 3378. PMID 37291228 DOI: 10.1038/s41467-023-39042-y |
0.356 |
|
| 2023 |
Ghorbani A, Avery LM, Sohaei D, Soosaipillai A, Richer M, Horbinski C, McCortney K, Xu W, Diamandis EP, Prassas I. Discovery of novel glioma serum biomarkers by proximity extension assay. Clinical Proteomics. 20: 12. PMID 36959545 DOI: 10.1186/s12014-023-09400-5 |
0.366 |
|
| 2023 |
Chatanaka MK, Sohaei D, Diamandis EP, Prassas I. Beyond the amyloid hypothesis: how current research implicates autoimmunity in Alzheimer's disease pathogenesis. Critical Reviews in Clinical Laboratory Sciences. 1-29. PMID 36941789 DOI: 10.1080/10408363.2023.2187342 |
0.359 |
|
| 2023 |
Ulndreaj A, Sohaei D, Thebault S, Pons-Belda OD, Fernandez-Uriarte A, Campbell C, Cheo D, Stengelin M, Sigal G, Freedman MS, Scarisbrick IA, Prassas I, Diamandis EP. Quantitation of neurofilament light chain protein in serum and cerebrospinal fluid from patients with multiple sclerosis using the MSD R-PLEX NfL assay. Diagnosis (Berlin, Germany). PMID 36788117 DOI: 10.1515/dx-2022-0125 |
0.353 |
|
| 2023 |
Khatab Z, Prassas I, Stengelin M, Diamandis EP. Prostate-Specific Antigen and Female Breast Cancer-Revisited. The Journal of Applied Laboratory Medicine. PMID 36760007 DOI: 10.1093/jalm/jfad002 |
0.347 |
|
| 2023 |
Pasic I, Ren AH, Nampoothiri RV, Prassas I, Lipton JH, Mattsson J, Diamandis EP, Michelis FV. Multiplex proteomics using proximity extension assay for the identification of protein biomarkers predictive of acute graft-vs.-host disease in allogeneic hematopoietic cell transplantation. Clinical Chemistry and Laboratory Medicine. PMID 36655501 DOI: 10.1515/cclm-2022-0916 |
0.372 |
|
| 2022 |
Ulndreaj A, Brinc D, Altan M, Pons-Belda OD, Fernandez-Uriarte A, Mu-Mosley H, Fattah F, von Itzstein MS, Soosaipillai A, Kulasingam V, Palaskas NL, Gerber DE, Diamandis EP, Heymach JV, Prassas I. Quantitation of cardiac troponin I in cancer patients treated with immune checkpoint inhibitors: a case-control study. Clinical Chemistry and Laboratory Medicine. PMID 36287134 DOI: 10.1515/cclm-2022-0471 |
0.393 |
|
| 2022 |
Sohaei D, Ulndreaj A, Mathew A, Campbell C, Stengelin M, Sigal G, Joe J, Romero D, Padmanabhan N, Ren A, Ghorbani A, Soosaipillai A, Kulasingam V, Prassas I, Diamandis EP. Sensitive Serology Measurements in the Saliva of Individuals with COVID-19 Symptoms Using a Multiplexed Immunoassay. The Journal of Applied Laboratory Medicine. PMID 36179121 DOI: 10.1093/jalm/jfac073 |
0.307 |
|
| 2022 |
Sohaei D, Hollenberg M, Janket SJ, Diamandis EP, Poda G, Prassas I. The therapeutic relevance of the Kallikrein-Kinin axis in SARS-cov-2-induced vascular pathology. Critical Reviews in Clinical Laboratory Sciences. 1-16. PMID 35930434 DOI: 10.1080/10408363.2022.2102578 |
0.35 |
|
| 2022 |
Ulndreaj A, Wang M, Misaghian S, Paone L, Sigal GB, Stengelin M, Campbell C, Van Nynatten LR, Soosaipillai A, Ghorbani A, Mathew A, Fraser DD, Diamandis EP, Prassas I. Patients with severe COVID-19 do not have elevated autoantibodies against common diagnostic autoantigens. Clinical Chemistry and Laboratory Medicine. PMID 35475723 DOI: 10.1515/cclm-2022-0239 |
0.365 |
|
| 2022 |
Ren A, Sohaei D, Ulndreaj A, Pons-Belda OD, Fernandez-Uriarte A, Zacharioudakis I, Sigal GB, Stengelin M, Mathew A, Campbell C, Padmanabhan N, Romero D, Joe J, Soosaipillai A, Kulasingam V, ... ... Prassas I, et al. Ultrasensitive assay for saliva-based SARS-CoV-2 antigen detection. Clinical Chemistry and Laboratory Medicine. PMID 35170269 DOI: 10.1515/cclm-2021-1142 |
0.322 |
|
| 2021 |
Miller MR, Robinson M, Fischer L, DiBattista A, Patel MA, Daley M, Bartha R, Dekaban GA, Menon RS, Shoemaker JK, Diamandis EP, Prassas I, Fraser DD. Putative Concussion Biomarkers Identified in Adolescent Male Athletes Using Targeted Plasma Proteomics. Frontiers in Neurology. 12: 787480. PMID 34987469 DOI: 10.3389/fneur.2021.787480 |
0.393 |
|
| 2021 |
Ren A, Prassas I, Sugumar V, Soosaipillai A, Bernardini M, Diamandis EP, Kulasingam V. Comparison of two multiplexed technologies for profiling >1,000 serum proteins that may associate with tumor burden. F1000research. 10: 509. PMID 34868557 DOI: 10.12688/f1000research.53364.1 |
0.429 |
|
| 2021 |
Lim B, Prassas I, Diamandis EP. From the amyloid hypothesis to the autoimmune hypothesis of Alzheimer's disease. Diagnosis (Berlin, Germany). PMID 34496166 DOI: 10.1515/dx-2021-0108 |
0.301 |
|
| 2021 |
Lim B, Grøntvedt GR, Bathala P, Kale SS, Campbell CT, Stengelin M, Sando SB, Prassas I, Diamandis EP, Bråthen G. CSF neurofilament light may predict progression from amnestic mild cognitive impairment to Alzheimer's disease dementia. Neurobiology of Aging. 107: 78-85. PMID 34403936 DOI: 10.1016/j.neurobiolaging.2021.07.013 |
0.321 |
|
| 2021 |
Fraser DD, Chen M, Ren A, Miller MR, Martin C, Daley M, Diamandis EP, Prassas I. Novel severe traumatic brain injury blood outcome biomarkers identified with proximity extension assay. Clinical Chemistry and Laboratory Medicine. PMID 34144643 DOI: 10.1515/cclm-2021-0103 |
0.344 |
|
| 2021 |
Pellizzari G, Martinez O, Crescioli S, Page R, Di Meo A, Mele S, Chiaruttini G, Hoinka J, Batruch I, Prassas I, Grandits M, López-Abente J, Bugallo-Blanco E, Ward M, Bax HJ, et al. Immunotherapy using IgE or CAR T cells for cancers expressing the tumor antigen SLC3A2. Journal For Immunotherapy of Cancer. 9. PMID 34112739 DOI: 10.1136/jitc-2020-002140 |
0.376 |
|
| 2021 |
Chen M, Ren AH, Prassas I, Soosaipillai A, Lim B, Fraser DD, Diamandis EP. Plasma Protein Profiling by Proximity Extension Assay Technology Reveals Novel Biomarkers of Traumatic Brain Injury-A Pilot Study. The Journal of Applied Laboratory Medicine. PMID 33778875 DOI: 10.1093/jalm/jfab004 |
0.378 |
|
| 2020 |
Music M, Iafolla M, Soosaipillai A, Batruch I, Prassas I, Pintilie M, Hansen AR, Bedard PL, Lheureux S, Spreafico A, Razak AA, Siu LL, Diamandis EP. Predicting response and toxicity to PD-1 inhibition using serum autoantibodies identified from immuno-mass spectrometry. F1000research. 9: 337. PMID 33299547 DOI: 10.12688/f1000research.22715.1 |
0.352 |
|
| 2020 |
Ren AH, Prassas I, Soosaipillai A, Jarvi S, Gallinger S, Kulasingam V, Diamandis EP. Investigating a novel multiplex proteomics technology for detection of changes in serum protein concentrations that may correlate to tumor burden. F1000research. 9: 732. PMID 33274048 DOI: 10.12688/F1000Research.24654.1 |
0.514 |
|
| 2020 |
Lim B, Prassas I, Diamandis EP. Alzheimer Disease Pathogenesis: The Role of Autoimmunity. The Journal of Applied Laboratory Medicine. PMID 33241314 DOI: 10.1093/jalm/jfaa171 |
0.306 |
|
| 2020 |
Di Meo A, Sohaei D, Batruch I, Alexandrou P, Prassas I, Diamandis EP. Proteomic Profiling of the Human Tissue and Biological Fluid Proteome. Journal of Proteome Research. PMID 33107741 DOI: 10.1021/acs.jproteome.0c00502 |
0.406 |
|
| 2020 |
Fraser DD, Cepinskas G, Patterson EK, Slessarev M, Martin C, Daley M, Patel MA, Miller MR, O'Gorman DB, Gill SE, Pare G, Prassas I, Diamandis E. Novel Outcome Biomarkers Identified With Targeted Proteomic Analyses of Plasma From Critically Ill Coronavirus Disease 2019 Patients. Critical Care Explorations. 2: e0189. PMID 32904064 DOI: 10.1097/CCE.0000000000000189 |
0.388 |
|
| 2020 |
Di Paolo CT, Diamandis EP, Prassas I. The role of kallikreins in inflammatory skin disorders and their potential as therapeutic targets. Critical Reviews in Clinical Laboratory Sciences. 1-16. PMID 32568598 DOI: 10.1080/10408363.2020.1775171 |
0.409 |
|
| 2020 |
Diamandis P, Prassas I, Diamandis EP. Antibody tests for COVID-19: drawing attention to the importance of analytical specificity. Clinical Chemistry and Laboratory Medicine. PMID 32386187 DOI: 10.1515/Cclm-2020-0554 |
0.387 |
|
| 2020 |
Filippou PS, Ren AH, Soosaipillai A, Safar R, Prassas I, Diamandis EP, Conner JR. Kallikrein-related peptidases protein expression in lymphoid tissues suggests potential implications in immune response. Clinical Biochemistry. PMID 31904348 DOI: 10.1016/J.Clinbiochem.2019.12.015 |
0.445 |
|
| 2020 |
Music M, Iafolla M, Soosaipillai A, Batruch I, Prassas I, Pintilie M, Hansen AR, Bedard PL, Lheureux S, Spreafico A, Razak AA, Siu LL, Diamandis EP. Predicting response and toxicity to PD-1 inhibition using serum autoantibodies identified from immuno-mass spectrometry F1000research. 9: 337. DOI: 10.12688/F1000Research.22715.1 |
0.432 |
|
| 2020 |
Music M, Iafolla M, Soosaipillai A, Batruch I, Prassas I, Siu LL, Diamandis EP. Abstract PR03: Immuno-mass spectrometric identification of serum biomarkers of response and toxicity to pembrolizumab Cancer Immunology Research. 8. DOI: 10.1158/2326-6074.Tumimm18-Pr03 |
0.517 |
|
| 2019 |
Lim B, Tsolaki M, Batruch I, Anastasiou A, Frontistis A, Prassas I, Diamandis EP. Putative autoantibodies in the cerebrospinal fluid of Alzheimer's disease patients. F1000research. 8: 1900. PMID 32089828 DOI: 10.12688/F1000Research.21140.1 |
0.483 |
|
| 2019 |
Lim B, Tsolaki M, Soosaipillai A, Brown M, Zilakaki M, Tagaraki F, Fotiou D, Koutsouraki E, Grosi E, Prassas I, Diamandis EP. Liquid biopsy of cerebrospinal fluid identifies neuronal pentraxin receptor (NPTXR) as a biomarker of progression of Alzheimer's disease. Clinical Chemistry and Laboratory Medicine. PMID 31415236 DOI: 10.1515/Cclm-2019-0428 |
0.415 |
|
| 2019 |
Music M, Iafolla MAJ, Ren AH, Soosaipillai A, Prassas I, Diamandis EP. Serum PD-1 is elevated after pembrolizumab treatment but has no predictive value. Molecular Cancer Therapeutics. PMID 31363009 DOI: 10.1158/1535-7163.Mct-19-0132 |
0.466 |
|
| 2019 |
Music M, Soosaipillai A, Batruch I, Prassas I, Bogdanos DP, Diamandis EP. Correction to: A proteome-wide immuno-mass spectrometric identification of serum autoantibodies. Clinical Proteomics. 16: 30. PMID 31346327 DOI: 10.1186/S12014-019-9250-4 |
0.411 |
|
| 2019 |
Music M, Soosaipillai A, Batruch I, Prassas I, Bogdanos DP, Diamandis EP. A proteome-wide immuno-mass spectrometric identification of serum autoantibodies. Clinical Proteomics. 16: 25. PMID 31249498 DOI: 10.1186/s12014-019-9246-0 |
0.422 |
|
| 2019 |
Di Paolo CT, Filippou PS, Yu Y, Poda G, Diamandis EP, Prassas I. Screening of chemical libraries in pursuit of kallikrein-5 specific inhibitors for the treatment of inflammatory dermatoses. Clinical Chemistry and Laboratory Medicine. PMID 31129650 DOI: 10.1515/Cclm-2019-0123 |
0.341 |
|
| 2019 |
Dimitrakopoulos L, Prassas I, Sieuwerts AM, Diamandis EP, Martens JWM, Charames GS. Proteome-wide onco-proteogenomic somatic variant identification in ER-positive breast cancer. Clinical Biochemistry. PMID 30684468 DOI: 10.1016/J.Clinbiochem.2019.01.005 |
0.39 |
|
| 2018 |
Music M, Prassas I, Diamandis EP. Optimizing cancer immunotherapy: Is it time for personalized predictive biomarkers? Critical Reviews in Clinical Laboratory Sciences. 1-14. PMID 30277835 DOI: 10.1080/10408363.2018.1499706 |
0.502 |
|
| 2018 |
Diamandis EP, Scorilas A, Prassas I, Plebani M. The International Society for Enzymology: a glorious history, a golden legacy. Clinical Chemistry and Laboratory Medicine. PMID 30157030 DOI: 10.1515/Cclm-2018-0766 |
0.336 |
|
| 2018 |
Filippou PS, Ren AH, Bala S, Papaioannou MD, Brinc D, Prassas I, Karakosta T, Diamandis EP. Biochemical characterization of human tissue kallikrein 15 and examination of its potential role in cancer. Clinical Biochemistry. PMID 29928903 DOI: 10.1016/J.Clinbiochem.2018.06.007 |
0.507 |
|
| 2017 |
Kulasingam V, Prassas I, Diamandis EP. Towards personalized tumor markers. Npj Precision Oncology. 1: 17. PMID 29872704 DOI: 10.1038/s41698-017-0021-2 |
0.466 |
|
| 2017 |
Dimitrakopoulos L, Prassas I, Diamandis EP, Charames GS. Onco-proteogenomics: Multi-omics level data integration for accurate phenotype prediction. Critical Reviews in Clinical Laboratory Sciences. 1-19. PMID 29025326 DOI: 10.1080/10408363.2017.1384446 |
0.408 |
|
| 2017 |
Filippou PS, Farkona S, Brinc D, Yu Y, Prassas I, Diamandis EP. Biochemical and Functional Characterization of the Human Tissue Kallikrein 9. The Biochemical Journal. PMID 28559305 DOI: 10.1042/Bcj20170174 |
0.453 |
|
| 2017 |
Briollais L, Ozcelik H, Xu J, Kwiatkowski M, Lalonde E, Sendorek DH, Fleshner NE, Recker F, Kuk C, Olkhov-Mitsel E, Juvet T, Prassas I, Trachtenberg J, Toi A, Fraser M, et al. Germline Mutations in the Kallikrein 6 Region and Predisposition for Aggressive Prostate Cancer. Journal of the National Cancer Institute. 109. PMID 28376164 DOI: 10.1093/Jnci/Djw258 |
0.44 |
|
| 2017 |
Dimitrakopoulos L, Prassas I, Berns EM, Foekens JA, Diamandis EP, Charames GS. Variant peptide detection utilizing mass spectrometry: laying the foundations for proteogenomic identification and validation. Clinical Chemistry and Laboratory Medicine. PMID 28157690 DOI: 10.1515/Cclm-2016-0947 |
0.417 |
|
| 2017 |
Yu Y, Prassas I, Muytjens CM, Diamandis EP. Proteomic and peptidomic analysis of human sweat with emphasis on proteolysis. Journal of Proteomics. PMID 28095327 DOI: 10.1016/J.Jprot.2017.01.005 |
0.459 |
|
| 2017 |
Briollais L, Ozcelik H, Xu J, Kwiatkowski M, Lalonde E, Sendorek DH, Fleshner NE, Recker F, Kuk C, Olkhov-Mitsel E, Savas S, Hanna S, Juvet T, Hunter GA, Friedlander M, ... ... Prassas I, et al. PD65-01 GERMLINE MUTATIONS IN THE KALLIKREIN 6 REGION AND PREDISPOSITION FOR AGGRESSIVE PROSTATE CANCER Journal of Urology. 197. DOI: 10.1016/J.Juro.2017.02.2951 |
0.413 |
|
| 2016 |
Muytjens CM, Vasiliou SK, Oikonomopoulou K, Prassas I, Diamandis EP. Putative functions of tissue kallikrein-related peptidases in vaginal fluid. Nature Reviews. Urology. PMID 27603220 DOI: 10.1038/Nrurol.2016.161 |
0.44 |
|
| 2016 |
Dimitrakopoulos L, Prassas I, Diamandis EP, Nesvizhskii A, Kislinger T, Jaffe J, Drabovich A. Proteogenomics: Opportunities and Caveats. Clinical Chemistry. 62: 551-7. PMID 26817480 DOI: 10.1373/Clinchem.2015.247858 |
0.457 |
|
| 2015 |
Korbakis D, Dimitromanolakis A, Prassas I, Davis GJ, Barber E, Reckamp KL, Blasutig I, Diamandis EP. Serum LAMC2 enhances the prognostic value of a multi-parametric panel in non-small cell lung cancer. British Journal of Cancer. 113: 484-91. PMID 26180921 DOI: 10.1038/Bjc.2015.171 |
0.481 |
|
| 2015 |
Yu Y, Prassas I, Dimitromanolakis A, Diamandis EP. Novel Biological Substrates of Human Kallikrein 7 Identified through Degradomics. The Journal of Biological Chemistry. 290: 17762-75. PMID 26032414 DOI: 10.1074/Jbc.M115.643551 |
0.468 |
|
| 2015 |
Prassas I, Eissa A, Poda G, Diamandis EP. Unleashing the therapeutic potential of human kallikrein-related serine proteases. Nature Reviews. Drug Discovery. 14: 183-202. PMID 25698643 DOI: 10.1038/Nrd4534 |
0.645 |
|
| 2015 |
Korbakis D, Prassas I, Brinc D, Batruch I, Krastins B, Lopez MF, Diamandis EP. Delineating monoclonal antibody specificity by mass spectrometry. Journal of Proteomics. 114: 115-24. PMID 25462431 DOI: 10.1016/J.Jprot.2014.11.004 |
0.433 |
|
| 2015 |
Korbakis D, Dimitromanolakis A, Prassas I, Davis GJ, Barber E, Reckamp KL, Blasutig I, Diamandis EP. Serum LAMC2 enhances the prognostic value of a multi-parametric panel in non-small cell lung cancer British Journal of Cancer. 113: 484-491. DOI: 10.1038/bjc.2015.171 |
0.374 |
|
| 2014 |
Chan A, Prassas I, Dimitromanolakis A, Brand RE, Serra S, Diamandis EP, Blasutig IM. Validation of biomarkers that complement CA19.9 in detecting early pancreatic cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 5787-95. PMID 25239611 DOI: 10.1158/1078-0432.Ccr-14-0289 |
0.503 |
|
| 2014 |
Sukumar N, Scott E, Dimitromanolakis A, Misiak A, Prassas I, Diamandis EP, Konvalinka A. Mining for single nucleotide variants (SNVs) at the kallikrein locus with predicted functional consequences. Biological Chemistry. 395: 1037-50. PMID 25153386 DOI: 10.1515/Hsz-2014-0136 |
0.427 |
|
| 2014 |
Cretu D, Prassas I, Saraon P, Batruch I, Gandhi R, Diamandis EP, Chandran V. Identification of psoriatic arthritis mediators in synovial fluid by quantitative mass spectrometry. Clinical Proteomics. 11: 27. PMID 25097465 DOI: 10.1186/1559-0275-11-27 |
0.717 |
|
| 2014 |
Yu Y, Prassas I, Diamandis EP. Putative kallikrein substrates and their (patho)biological functions. Biological Chemistry. 395: 931-43. PMID 24854536 DOI: 10.1515/Hsz-2014-0129 |
0.444 |
|
| 2014 |
Karagiannis GS, Pavlou MP, Saraon P, Musrap N, Xie A, Batruch I, Prassas I, Dimitromanolakis A, Petraki C, Diamandis EP. In-depth proteomic delineation of the colorectal cancer exoproteome: Mechanistic insight and identification of potential biomarkers. Journal of Proteomics. 103: 121-36. PMID 24681409 DOI: 10.1016/J.Jprot.2014.03.018 |
0.763 |
|
| 2014 |
Prassas I, Diamandis EP. Translational researchers beware! Unreliable commercial immunoassays (ELISAs) can jeopardize your research. Clinical Chemistry and Laboratory Medicine. 52: 765-6. PMID 24497227 DOI: 10.1515/Cclm-2013-1078 |
0.357 |
|
| 2014 |
Prassas I, Brinc D, Farkona S, Leung F, Dimitromanolakis A, Chrystoja CC, Brand R, Kulasingam V, Blasutig IM, Diamandis EP. False biomarker discovery due to reactivity of a commercial ELISA for CUZD1 with cancer antigen CA125. Clinical Chemistry. 60: 381-8. PMID 24097894 DOI: 10.1373/Clinchem.2013.215236 |
0.52 |
|
| 2013 |
Kosanam H, Prassas I, Chrystoja CC, Soleas I, Chan A, Dimitromanolakis A, Blasutig IM, Rückert F, Gruetzmann R, Pilarsky C, Maekawa M, Brand R, Diamandis EP. Laminin, gamma 2 (LAMC2): a promising new putative pancreatic cancer biomarker identified by proteomic analysis of pancreatic adenocarcinoma tissues. Molecular & Cellular Proteomics : McP. 12: 2820-32. PMID 23798558 DOI: 10.1074/Mcp.M112.023507 |
0.525 |
|
| 2012 |
Prassas I, Chrystoja CC, Makawita S, Diamandis EP. Bioinformatic identification of proteins with tissue-specific expression for biomarker discovery. Bmc Medicine. 10: 39. PMID 22515324 DOI: 10.1186/1741-7015-10-39 |
0.534 |
|
| 2012 |
Karagiannis GS, Petraki C, Prassas I, Saraon P, Musrap N, Dimitromanolakis A, Diamandis EP. Proteomic signatures of the desmoplastic invasion front reveal collagen type XII as a marker of myofibroblastic differentiation during colorectal cancer metastasis. Oncotarget. 3: 267-85. PMID 22408128 DOI: 10.18632/Oncotarget.451 |
0.753 |
|
| 2012 |
Chrystoja C, Kosanam H, Prassas I, Chan A, Dimitromanolakis A, Makawita S, Soosaipillai A, Blasutig I, Diamandis EP. Abstract A3: Validation of candidate serum biomarkers demonstrates the potential of CUZD1 and LAMC2 to complement CA19.9 for pancreatic cancer diagnosis. Cancer Research. 72. DOI: 10.1158/1538-7445.Panca2012-A3 |
0.522 |
|
| 2011 |
Prassas I, Karagiannis GS, Batruch I, Dimitromanolakis A, Datti A, Diamandis EP. Digitoxin-induced cytotoxicity in cancer cells is mediated through distinct kinase and interferon signaling networks. Molecular Cancer Therapeutics. 10: 2083-93. PMID 21859838 DOI: 10.1158/1535-7163.Mct-11-0421 |
0.624 |
|
| 2011 |
Prassas I, Makawita S, Diamandis E. Abstract 5075: An integratedin silicoand proteomic approach towards the identification of novel cancer biomarkers based on tissue specificity Cancer Research. 71: 5075-5075. DOI: 10.1158/1538-7445.Am2011-5075 |
0.554 |
|
| 2009 |
Angelopoulou K, Prassas I, Yousef GM. The canine kallikrein-related peptidase 14: structural characterization, alternative splicing and differential expression in mammary cancer. Gene. 446: 68-74. PMID 19619623 DOI: 10.1016/J.Gene.2009.07.007 |
0.552 |
|
| 2008 |
Prassas I, Diamandis EP. Novel therapeutic applications of cardiac glycosides. Nature Reviews. Drug Discovery. 7: 926-35. PMID 18948999 DOI: 10.1038/Nrd2682 |
0.436 |
|
| 2008 |
Prassas I, Paliouras M, Datti A, Diamandis EP. High-throughput screening identifies cardiac glycosides as potent inhibitors of human tissue kallikrein expression: implications for cancer therapies. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 5778-84. PMID 18794087 DOI: 10.1158/1078-0432.Ccr-08-0706 |
0.523 |
|
| Show low-probability matches. |